Investor Presentation First Nine Months of 2023
43
Investor presentation
First nine months of 2023
GLP-1 mechanism of action and potential therapeutic
opportunities
GLP-1 mechanism of action when blood
sugar levels increase
Creates sense of satiety in the brain
Diabetes
Brain
CVD
Semaglutide holds a plethora of therapeutic opportunities¹
FOCUS - Diabetic retinopathy outcomes trial
Semaglutide s.c; ~1,500 patients, T2D ≥10 years
SOUL - Cardiovascular outcomes trial
Oral semaglutide; ~9,600 patients, T2D, established CVD or CKD
SELECT - Cardiovascular outcomes trial
Obesity Semaglutide 2.4 mg, ~17,500 patients with obesity and without
diabetes, event driven
PAD
Brain
disorders
Heart
Failure
Semaglutide in MASH
Semaglutide s.c.; phase 3 and 2 trials
FLOW - Chronic kidney disease outcomes trial
Semaglutide 1.0 mg; ~3,200 patients, T2D, moderate to severe CKD
STRIDE - Peripheral artery disease trial
Semaglutide 1.0 mg; ~ 800 patients with T2D and PAD
Alzheimer's Disease
Oral Semaglutide 14 mg; ~ 3,700 patients with early Alzheimer's
disease
STEP - HFPEF
Semaglutide 2.4 mg; ~ 600 patients with obesity-related HFPEF
Reduces
glucagon
secretion in
the liver
GLP-1
Liver
Slows
gastric
emptying
MASH
Stomach
CKD
1 List is not exhaustive
Pancreas
Increases insulin secretion in the
pancreas
Sc: Subcutaneous; T2D: Type 2 diabetes; CVD: Cardiovascular disease; CKD: Chronic kidney disease; MASH: Metabolic dysfunction-associated steatohepatitis; PAD: Peripheral artery disease
Novo NordiskⓇView entire presentation